MAGELLAN-I: Novel regimen yields strong results in experienced patients with RAVs

BARCELONA —  Combination therapy with ABT-493, a novel NS3/4A protease inhibitor, and ABT-530, a pangenotypic NS5A inhibitor, produced sustained virologic response rates around 90% in a cohort of treatment-experienced patients, including those with resistance-associated variants, according to findings presented at the International Liver Congress. Fred Poordad, MD, of The...

Read More

AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals

– 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy with DAAs in a modified intent-to-treat analysis – 91 percent achieved SVR12 with RBV in the primary intent-to-treat analysis;...

Read More